[Dadeemelee]

Oorspronkelijk geplaatst door Hoofdstraat

De CDC zegt nu duidelijk dat de vaccins op basis van hartspierontstekingen alleen al meestal gevaarlijker zijn dan de ziekte of dan toch geen duidelijk voordeel opleveren. Enkel voor kinderen met bepaalde morbiditeiten is het nog voordelig.

Dan blijft nog de vraag wat er zal gebeuren bij boosters, en als ze geen boosters krijgen gaan ze alsnog nog Covid-19 opdoen wat het hele vaccin gebeuren nutteloos heeft gemaakt.


https://www.news-medical.net/news/20...-children.aspx

Following the second dose of the vaccine, the group found a 162.2 per million incidence rate of cardiac adverse events in boys aged 12-15, around three times higher than estimated by the CDC. In boys aged 16-17, the group also found a higher rate than estimated by the CDC by around 40%, 94 individuals per million vaccinations. The rate of adverse events was also higher than estimated by the CDC amongst girls, 13 and 13.4 per million in those aged 12-15 or 16-17, respectively.

Therefore, the risk of cardiac adverse events following the second dose of the mRNA vaccine could be around 3.7 times more likely than hospitalization due to COVID-19 in healthy 12-15-year-old boys during periods when the pandemic is better under control 2.1 times in 16-17-year-olds. The group found that this trend remains even when SARS-CoV-2 transmission rates are high, with vaccination being riskier than hospitalization from COVID-19. However, for those with at least one COVID-19 comorbidity, receiving the vaccine was safer than the risk of being hospitalized during periods of high transmission, but not when COVID-19 hospitalization rates were low.

The long-term health effect of the mRNA vaccines on teenage boys is unknown. Few clinical trials have been conducted due to the early observation of adverse events. The group suggests that vaccination of this age group could be done on a case-by-case basis, allowing the risks and benefits to be weighed for each individual.

Dat artikel is al in een andere draad besproken.